{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:25:15Z","timestamp":1774607115561,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Im klinischen Alltag sind die Diagnose und die Behandlung der Optikuskompression bei endokriner Orbitopathie (EO) immer noch eine gro\u00dfe Herausforderung. In dieser Studie untersuchen wir die funktionellen Ergebnisse in Bezug auf den bestkorrigierten Visus (BCVA) und Gesichtsfeld(GF)-Defekte bei N.-opticus-Kompression (OK) bei den Patienten mit EO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patienten und Methoden<\/jats:title>\n                <jats:p>In diese retrospektive Studie wurden 51\u00a0Patienten (96\u00a0Augen) mit der Diagnose einer gesicherten OK zwischen 2010 und 2020 eingeschlossen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Nach der Diagnose wurden 16\u00a0Patienten (27\u00a0Augen) ausschlie\u00dflich konservativ nur mit einer Steroidsto\u00dftherapie behandelt, 67\u00a0Augen erhielten zus\u00e4tzlich eine chirurgische orbitale Dekompression, w\u00e4hrend 1\u00a0Patient (2\u00a0Augen) beide Behandlungsmethoden ablehnte. Bei 74\u00a0Augen (77,1\u202f%) wurde eine Verbesserung des Visus \u2265\u202f2\u00a0Linien nach der Behandlung \u00fcber einen mittleren Zeitraum von 31,7\u00a0Wochen dokumentiert. Es zeigte sich nur bei\u00a022 (27,2\u202f%) der 81\u00a0Augen ein kompletter R\u00fcckgang der GF-Defekte (mittlerer Zeitraum: 9,9\u00a0Wochen). Als wir die Analyse auf Patienten beschr\u00e4nkten, bei denen die letzte Untersuchung mindestens 6\u00a0Monate zur\u00fccklag, stellten wir fest, dass 33\u00a0Augen (61,1\u202f%) von 54\u00a0Augen immer noch einen GF-Defekt aufwiesen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Anhand unserer Daten zeigten mehr als die H\u00e4lfte der Patienten mit Optikuskompression (61,5\u202f%) eine sehr gute Prognose mit einem endg\u00fcltigen BCVA \u2265\u202f0,8 bei der letzten Untersuchung. Allerdings zeigten nur 22\u00a0Augen (27,2\u202f%) eine unauff\u00e4llige Gesichtsfelduntersuchung, w\u00e4hrend 33\u00a0Augen (61,1\u202f%) nach einer Nachbeobachtungszeit von mindestens 6\u00a0Monaten Restdefekte hatten. Diese Ergebnisse deuten darauf hin, dass sich der Visus zwar sehr gut rehabilitiert, die Optikuskompression bei EO jedoch bei den meisten Patienten unabh\u00e4ngig von der Behandlungsmethode Spuren im Gesichtsfeld hinterl\u00e4sst.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-023-01865-x","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:01:37Z","timestamp":1683306097000},"page":"832-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optikuskompression bei endokriner Orbitopathie","Thyroid Eye Disease\u2014Compressive Optic Neuropathy"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-6781","authenticated-orcid":false,"given":"Aylin","family":"Garip Kuebler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Halfter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Klingenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Neuhann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Enders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hintschich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"1865_CR1","first-page":"477","volume":"92","author":"GB Bartley","year":"1994","unstructured":"Bartley\u00a0GB (1994) The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92:477\u2013588","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"11","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","volume":"95","author":"JM Neigel","year":"1988","unstructured":"Neigel\u00a0JM, Rootman\u00a0J, Belkin\u00a0RI, Nugent\u00a0RA, Drance\u00a0SM, Beattie\u00a0CW et\u00a0al (1988) Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 95(11):1515\u20131521","journal-title":"Ophthalmology"},{"issue":"1","key":"1865_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits\u00a0MP, Prummel\u00a0MF, Wiersinga\u00a0WM, Koornneef\u00a0L (1997) Clinical activity score as a\u00a0guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1865_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ajo.2019.12.005","volume":"213","author":"SK Freitag","year":"2020","unstructured":"Freitag\u00a0SK, Tanking\u00a0T (2020) A nomenclature to describe the sequence of visual field defects in progressive thyroid eye disease-compressive optic neuropathy (an American ophthalmological society thesis). Am J Ophthalmol 213:293\u2013305","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1865_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41433-021-01504-2","volume":"36","author":"A Garip Kuebler","year":"2022","unstructured":"Garip Kuebler\u00a0A, Halfter\u00a0K, Reznicek\u00a0L, Klingenstein\u00a0A, Priglinger\u00a0S, Hintschich\u00a0C (2022) Evaluating the interreader agreement and intrareader reproducibility of visual field defects in thyroid eye disease\u2014compressive optic neuropathy. Eye (Lond) 36(4):724\u2013732. https:\/\/doi.org\/10.1038\/s41433-021-01504-2","journal-title":"Eye (Lond)"},{"key":"1865_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/TCRM.S193018","volume":"15","author":"Y Wang","year":"2019","unstructured":"Wang\u00a0Y, Patel\u00a0A, Douglas\u00a0RS (2019) Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag 15:1305\u20131318","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41433-020-0897-x","volume":"34","author":"A Garip Kuebler","year":"2020","unstructured":"Garip Kuebler\u00a0A, Wiecha\u00a0C, Reznicek\u00a0L, Klingenstein\u00a0A, Halfter\u00a0K, Priglinger\u00a0S et\u00a0al (2020) Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy. Eye (Lond) 34(9):1702\u20131709","journal-title":"Eye (Lond)"},{"issue":"7","key":"1865_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bjophthalmol-2020-316433","volume":"105","author":"A Garip-Kuebler","year":"2021","unstructured":"Garip-Kuebler\u00a0A, Halfter\u00a0K, Reznicek\u00a0L, Klingenstein\u00a0A, Priglinger\u00a0S, Hintschich\u00a0CR (2021) Subclinical dysthyroid optic neuropathy: tritan deficiency as an early sign of dysthyroid optic neuropathy. Br J Ophthalmol 105(7):1019\u20131023","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1865_CR9","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00417-021-05227-8","volume":"259","author":"A Garip Kuebler","year":"2021","unstructured":"Garip Kuebler\u00a0A, Halfter\u00a0K, Reznicek\u00a0L, Klingenstein\u00a0A, Priglinger\u00a0S, Rudolph\u00a0G et\u00a0al (2021) A pathological indicator for dysthyroid optic neuropathy: tritan color vision deficiency. Graefes Arch Clin Exp Ophthalmol 259(11):3421\u20133426","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1865_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0002-9394(14)73194-0","volume":"116","author":"JA Garrity","year":"1993","unstructured":"Garrity\u00a0JA, Fatourechi\u00a0V, Bergstralh\u00a0EJ, Bartley\u00a0GB, Beatty\u00a0CW, DeSanto\u00a0LW et\u00a0al (1993) Results of transantral orbital decompression in 428\u00a0patients with severe Graves\u2019 ophthalmopathy. Am J Ophthalmol 116(5):533\u2013547","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","volume":"24","author":"N Curro","year":"2014","unstructured":"Curro\u00a0N, Covelli\u00a0D, Vannucchi\u00a0G, Campi\u00a0I, Pirola\u00a0G, Simonetta\u00a0S et al (2014) Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid 24(5):897\u2013905","journal-title":"Thyroid"},{"issue":"4","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D McKeag","year":"2007","unstructured":"McKeag\u00a0D, Lane\u00a0C, Lazarus\u00a0JH, Baldeschi\u00a0L, Boboridis\u00a0K, Dickinson\u00a0AJ et\u00a0al (2007) Clinical features of dysthyroid optic neuropathy: a\u00a0European group on Graves\u2019 orbitopathy (EUGOGO) survey. Br J Ophthalmol 91(4):455\u2013458","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/IOP.0000000000001224","volume":"35","author":"S Oropesa","year":"2019","unstructured":"Oropesa\u00a0S, Dunbar\u00a0KE, Godfrey\u00a0KJ, Callahan\u00a0AB, Campbell\u00a0AA, Kazim\u00a0M (2019) Predominant contribution of superior rectus-levator complex enlargement to optic neuropathy and inferior visual field defects in thyroid eye disease. Ophthalmic Plast Reconstr Surg 35(3):262\u2013265","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"1865_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/01676830.2017.1314510","volume":"36","author":"CJ Choi","year":"2017","unstructured":"Choi\u00a0CJ, Oropesa\u00a0S, Callahan\u00a0AB, Glass\u00a0LR, Teo\u00a0L, Cestari\u00a0DM et\u00a0al (2017) Patterns of visual field changes in thyroid eye disease. Orbit 36(4):201\u2013207","journal-title":"Orbit"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01865-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-023-01865-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01865-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:04:49Z","timestamp":1691492689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-023-01865-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s00347-023-01865-x","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"5 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Garip Kuebler, K.\u00a0Halfter, A.\u00a0Klingenstein, L.\u00a0Neuhann, C.\u00a0Enders, S.\u00a0Priglinger und C.\u00a0Hintschich geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}